- Previous Close
0.2620 - Open
0.2750 - Bid 0.2696 x --
- Ask 0.2829 x --
- Day's Range
0.2750 - 0.2750 - 52 Week Range
0.2000 - 0.3280 - Volume
17,500 - Avg. Volume
10,148 - Market Cap (intraday)
37.357M - Beta (5Y Monthly) --
- PE Ratio (TTM)
9.17 - EPS (TTM)
0.0300 - Earnings Date Feb 12, 2025 - Feb 17, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for enabling the collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. It also provides customer vial filling services. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.
www.microbix.comRecent News: MBXBF
View MorePerformance Overview: MBXBF
Trailing total returns as of 12/20/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MBXBF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MBXBF
View MoreValuation Measures
Market Cap
37.60M
Enterprise Value
33.09M
Trailing P/E
10.72
Forward P/E
17.24
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.32
Price/Book (mrq)
1.89
Enterprise Value/Revenue
2.03
Enterprise Value/EBITDA
6.30
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
--
Diluted EPS (ttm)
0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--